Feb 13 (Reuters) - Robert F. Kennedy Jr, a vaccine critic who has pledged to tackle chronic disease, was confirmed by the U.S. Senate as Health Secretary on Thursday, after overcoming resistance from the medical establishment and members of Congress with promises to limit his role in vaccine policy.
As head of the health department, which oversees more than $3 trillion in healthcare spending, Kennedy would have authority over agencies including the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention $(CDC)$.
Here are some pending regulatory decisions and meetings on vaccines coming up over the next few months:
EXPECTED DATE | REGULATORY EVENT | COMPANY |
|---|---|---|
Feb 14 | FDA decision on company's 5-in-1 meningococcal vaccine candidate | GSK plc GSK.L |
Feb 14 | FDA decision on company's chikungunya vaccine, Vimkunya, in individuals 12 years and older | Bavarian Nordic BAVA.CO |
Feb 26 | CDC's Advisory Committee on Immunization Practices (ACIP) to vote on GSK's meningococcal vaccine | GSK plc GSK.L |
Feb 26 | CDC's ACIP to vote on company's influenza vaccine | AstraZenecaAZN.L |
Feb 27 | CDC's ACIP to vote on company's Respiratory Syncytial Virus vaccine in high-risk adults 18- 49 years old | GSK plc GSK.L |
Feb 27 | CDC's ACIP to vote on company's Respiratory Syncytial Virus vaccine, mRESVIA, in high-risk adults 18 to 59 years old | Moderna MRNA.O |
April | FDA decision on Emergency Use Authorization of company's 2024-2025 formula COVID-19 vaccine (NVX-CoV2705) | Novavax NVAX.O |
May 31 | FDA decision on company's next-generation COVID-19 vaccine (mRNA-1283) | Moderna MRNA.O |
June 10 | FDA decision on company's monoclonal antibody designed to protect infants from RSV disease | Merck MRK.N |
(Reporting by Mariam Sunny in Bengaluru; Editing by Anil D'Silva)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。